The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment

BACKGROUND: Treatment of ER(+) breast cancer with intramuscular formulation of Formestane (4-OHA) shrinks the tumor within weeks. Since the tedious way of intramuscular administration and side effects are not suited for adjuvant treatment, Formestane was withdrawn from the market. A new transdermal...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lanyang, Zhu, Lei, Shen, Chen, Hou, Xiaoming, Chen, Youyou, Zou, Linglin, Qiang, Huiyan, Teichmann, Alexander T., Fu, Wenguang, Luo, Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087521/
https://www.ncbi.nlm.nih.gov/pubmed/37056757
http://dx.doi.org/10.3389/fimmu.2023.1041525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087521/
https://www.ncbi.nlm.nih.gov/pubmed/37056757
http://dx.doi.org/10.3389/fimmu.2023.1041525

Ejemplares similares